221 related articles for article (PubMed ID: 1279241)
21. [Tumor necrosis factor-alpha--phase I and phase II clinical trials].
Chciałowski A; Targowski T; Bajera I; Jahnz-Rózyk K
Pol Merkur Lekarski; 1997 Jun; 2(12):396-9. PubMed ID: 9424335
[TBL] [Abstract][Full Text] [Related]
22. [Current status of immunotherapy in oncology].
Zielinski C
Acta Med Austriaca; 1991; 18(1):20-4. PubMed ID: 1713730
[TBL] [Abstract][Full Text] [Related]
23. Cytokine-based therapy for melanoma: pre-clinical studies.
Shurin MR; Kirkwood JM; Esche C
Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930
[TBL] [Abstract][Full Text] [Related]
24. [Expectations in the clinical application of human-recombinant cytokines. 3) Tumor necrosis factor and lymphotoxins].
Kawakami M
Nihon Rinsho; 1988 May; 46(5):1099-104. PubMed ID: 3137380
[No Abstract] [Full Text] [Related]
25. Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha.
Yang SC; Owen-Schaub L; Mendiguren-Rodriguez A; Grimm EA; Hong WK; Roth JA
J Thorac Cardiovasc Surg; 1990 Jan; 99(1):8-12; discussion 12-3. PubMed ID: 2152954
[TBL] [Abstract][Full Text] [Related]
26. Immunological monitoring and clinical trials of biological response modifiers.
Kopp WC; Holmlund JT; Urba WJ
Cancer Chemother Biol Response Modif; 1994; 15():226-86. PubMed ID: 7540029
[No Abstract] [Full Text] [Related]
27. [Biotherapy of cancer].
Subirá ML; Brugarolas A
Rev Clin Esp; 1992 Jun; 191(2):102-8. PubMed ID: 1380172
[No Abstract] [Full Text] [Related]
28. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor.
Neta R; Oppenheim JJ; Douches SD
J Immunol; 1988 Jan; 140(1):108-11. PubMed ID: 2447166
[TBL] [Abstract][Full Text] [Related]
29. Recombinant interleukin-2: a biological response modifier.
Kintzel PE; Calis KA
Clin Pharm; 1991 Feb; 10(2):110-28. PubMed ID: 2009728
[TBL] [Abstract][Full Text] [Related]
30. [BRM in the treatment of cancer].
Takaku F
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-3):1597-602. PubMed ID: 2454612
[TBL] [Abstract][Full Text] [Related]
31. [Enhancement of host defence against infection with Listeria monocytogenes in newborn mice by various recombinant cytokines].
Chen Y
Hokkaido Igaku Zasshi; 1991 Jan; 66(1):41-8. PubMed ID: 1900802
[TBL] [Abstract][Full Text] [Related]
32. [Possibilities and limits of the use of interferons in the clinic].
Ludwig CU
Schweiz Med Wochenschr; 1989 Nov; 119(44):1539-43. PubMed ID: 2479977
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
34. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
[TBL] [Abstract][Full Text] [Related]
35. [Interferons, interleukin-2 and tumor necrosis factor. New approaches to cancer therapy].
Oettgen HF
Arzneimittelforschung; 1987 Feb; 37(2A):251-5. PubMed ID: 2436634
[TBL] [Abstract][Full Text] [Related]
36. [Clinical application of IL-1 beta].
Kitamura K; Takaku F
Tanpakushitsu Kakusan Koso; 1991 May; 36(7):1458-65. PubMed ID: 1871368
[No Abstract] [Full Text] [Related]
37. Interferons and other cytokines in head and neck cancer.
Hamasaki VK; Vokes EE
Med Oncol; 1995 Mar; 12(1):23-33. PubMed ID: 8542243
[TBL] [Abstract][Full Text] [Related]
38. Preclinical study of sequential tumor necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms.
Moore AS; Theilen GH; Newell AD; Madewell BR; Rudolf AR
Cancer Res; 1991 Jan; 51(1):233-8. PubMed ID: 1899040
[TBL] [Abstract][Full Text] [Related]
39. [Interleukin-1 and interleukin-2].
Uhl D
Med Monatsschr Pharm; 1990 Oct; 13(10):298-302. PubMed ID: 2247016
[No Abstract] [Full Text] [Related]
40. Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC).
Oldham RK; Lewko WM; Good RW; Sharp E
In Vivo; 1994; 8(5):653-63. PubMed ID: 7537108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
